[Pharmacokinetic studies on cefsulodin in perinatal period].
Pharmacokinetic studies on cefsulodin (CFS) were carried out in perinatal mothers and infants. The results obtained are summarized as follows. 1. CFS was promptly absorbed upon intravenous drip infusion in pregnant women, producing dose-related peak serum levels. Placental transference to the fetus occurred quickly and at high levels. Upon intravenous drip infusion of 1-2 g of CFS, drug concentration of the cord blood and amniotic fluid exceeded MICs of clinically isolated strains of Pseudomonas aeruginosa. These levels in cord blood ranged 3.3-16.9 micrograms/ml upon 1 g intravenous drip infusion and 0.8-21.6 micrograms/ml upon 2 g intravenous drip infusion, and in amniotic fluid they were 1.3-15.6 micrograms/ml upon 1 g administration and 5.5-17.9 micrograms/ml upon 2 g administration. The drug was transferred into newborn infant through placenta, showing no tendency to accumulate. According to the above results, it appears possible to successfully prevent or treat perinatal infections through administration of the dose of 1-2 g twice daily. 2. Moreover, newborn infants delivered from mothers receiving CFS administration showed no laboratory test abnormalities. 3. The penetration of CFS into mother's milk occurred at low levels, and the transference from milk to newborn infants appeared to occur at even low levels. The above results have demonstrated that CFS is a clinically useful antibiotic for prophylaxis and treatment of perinatal Pseudomonas infections.
Cho
N
N
Department of Obstetrics and Gynecology, School of Medicine, Showa University.
Fukunaga
K
K
Kunii
K
K
D002441:Cefsulodin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005333:Fetus / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn / Q000378:metabolism*; D007232:Infant, Newborn, Diseases / Q000517:prevention & control; D008297:Male; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy / Q000378:metabolism*; D011552:Pseudomonas Infections / Q000517:prevention & control; D011550:Pseudomonas aeruginosa / Q000187:drug effects
D002441:Cefsulodin